BioSpace News Archive

With over 20 years of financial and capital markets experience, Kevin joins the senior executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilizing Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.

A key finding is that Myriad’s EndoPredict significantly outperformed Oncotype DX Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.

Avillion is focused on this collaborative approach to advancing the development of late-stage clinical candidates for pharmaceutical company partners.

Aziyo Biologics, Inc. and Cook Biotech Inc. today announced the expansion of the Aziyo Bio Envelope franchise by entering into additional exclusive global license agreements expanding the applications for the Bio Envelope product into the field of neuromodulation.

TREMFYA data from eight additional abstracts will be presented at the AAD Annual Meeting, including an oral presentation of a pooled analysis from the Phase 3 VOYAGE 1 and 2 trials evaluating consistency of response by weight across subgroups of patients through week 24.

The stocks of approximately 10,000 companies are traded daily in the multi-tiered OTC Markets, but only companies in the top tier qualify to trade on the OTCQX. T

Pragma Pharmaceuticals is pleased to announce that it is planning the launch of Decadron (dexamethasone) .5, .75, 4 and 6 mg tablets in early 2018.

The company officially entered the market at the 2018 AAD Annual Meeting in San Diego, California.

Evid Science has successfully secured seed funding from TKS I, a new private equity fund dedicated to early stage life science companies.

The data will be presented during the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in San Diego, CA from February 16-18.